Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

The reversibility of amivantamab-related toxicities suggests its promising utility in patients with EGFR exon 20 insertion mutations NSCLC.

Authors

Institutions

Publication Details

Journal
BMC Pulmonary Medicine
Published
2025-02-06
DOI
https://doi.org/10.1186/s12890-025-03509-z
Citations
7
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
10.63
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

Jing Zhang, Wenjie Li
7 citations
BMC Pulmonary Medicine
Lung Cancer Treatments and Mutations
10.63
article

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

Jing Zhang, Wenjie Li
article en
7 citations

Abstract

The reversibility of amivantamab-related toxicities suggests its promising utility in patients with EGFR exon 20 insertion mutations NSCLC.

BMC Pulmonary MedicineVol. 25(1)
Fudan University (CN), Nanfang Hospital (CN), Shanghai Second People's Hospital (CN), Southern Medical University (CN)
Good health and well-being
Openalex Percentile: Top 2%
Lung Cancer Treatments and Mutations
10.63
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer — Jing Zhang, Wenjie Li · BMC Pulmonary Medicine (2025) | TGRS Research Map | TGRS